Alector Grants Genentech Rights to AL050

The Tip Desk · October 27, 2026 · 1 min read

The biotech licenses its brain-penetrant GCase therapy for a $100 million upfront payment plus up to $1.17 billion in milestones and tiered royalties.

Alector, Inc. (ALEC) granted Genentech exclusive worldwide rights to develop and commercialize AL050, its brain-penetrant engineered glucocerebrosidase enzyme replacement therapy, in a deal that includes a $100 million upfront payment, potential milestone payments of up to $1.17 billion, and tiered royalties on net sales.

The company said it retains ownership of ABC and keeps full rights to apply the platform across its wholly owned pipeline.

Deficient GCase activity is increasingly recognized as a contributor to Parkinson’s Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency, said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

The collaboration is structured as a worldwide exclusive license rather than a full asset sale: Genentech takes development and commercialization of AL050, while Alector keeps the ABC platform and the right to use it on other programs it owns.

The financial package is staged. Alector will receive the $100 million upfront payment; the remaining value sits in milestone payments of up to $1.17 billion and in tiered royalties on net sales, which depend on later development and commercial outcomes.

Rosenthal’s comment framed the scientific gap the license is meant to fill: GCase deficiency is being linked more often to Parkinson’s Disease, and no approved therapy yet targets the enzyme deficiency itself.

Alector’s stated position is that it is not giving up the underlying technology. It keeps ABC and the ability to apply the platform across its wholly owned pipeline, so the Genentech deal covers AL050 specifically rather than the broader GCase ERT franchise.

The company did not specify an expected close date.